ICARO BOSZCZOWSKI
Projetos de Pesquisa
Unidades Organizacionais
PAHC, Hospital das Clínicas, Faculdade de Medicina - Médico
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/49 - Laboratório de Protozoologia, Hospital das Clínicas, Faculdade de Medicina
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/49 - Laboratório de Protozoologia, Hospital das Clínicas, Faculdade de Medicina
9 resultados
Resultados de Busca
Agora exibindo 1 - 9 de 9
- Carbapenem-resistant Enterobacteriaceae in patients admitted to the emergency department: prevalence, risk factors, and acquisition rate(2017) SALOMAO, M. C.; GUIMARAES, T.; DUAILIBI, D. F.; PERONDI, M. B. M.; LETAIF, L. S. H.; MONTAL, A. C.; ROSSI, F.; CURY, A. P.; DUARTE, A. J. S.; LEVIN, A. S.; BOSZCZOWSKI, I.Background: Carbapenem-resistant Enterobacteriaceae (CRE) have been reported worldwide and are associated with high mortality rates. Intestinal colonization acts as a reservoir and fosters exchange of resistance mechanisms. Aim: To investigate the prevalence of patients harbouring CRE on hospital admission, risk factors associated, and the acquisition rate within the emergency department (ED). Methods: This was a cross-sectional survey with 676 patients consecutively admitted to the ED study during the months of May to July 2016. A questionnaire was performed and rectal swabs were collected from patients on admission, for culture and for multiplex real-time polymerase chain reaction (PCR). If the patient was hospitalized for more than one week in the ED, samples were taken again to determine the acquisition rate of CRE. Findings: Forty-six patients were colonized; all positive PCR were Klebsiella pneumoniae carbapenemase. The acquisition rate was 18%. Previous exposure to healthcare in the last year, liver disease, and use of antibiotics in the last month were risk factors for colonization. Six patients with no previous exposure to healthcare were CRE-colonized on admission, suggesting transmission of CRE within the community. Conclusion: Screening of high-risk patients on admission to the ED is a strategy to early identify CRE carriage and may contribute to control CRE dissemination.
- Crude Mortality Associated With the Empirical Use of Polymyxins in Septic Patients in a Setting of High Prevalence of Carbapenem-Resistant Gram-negative Bacteria: Retrospective Analysis of a Cohort(2023) BEZERRA, Camila L. P. A. M.; JR, Eusebio L. dos Santos; OLIVEIRA, Maura S.; DIAS, Maria Beatriz S.; LEVIN, Anna S.; FREIRE, Maristela P.; BOSZCZOWSKI, Icaro; SALOMAO, Matias C.Background Our aim in this retrospective cohort study was to assess the impact on mortality of the empirical use of polymyxin as therapy for carbapenem-resistant gram-negative bacteria (CR-GNB) in septic patients. The study was performed at a tertiary academic hospital in Brazil, from January 2018 to January 2020, the pre-coronavirus disease 2019 period. Methods We included 203 patients with suspected sepsis. The first doses of antibiotics were prescribed from a ""sepsis antibiotic kit"", which contained a selection of drugs, including polymyxin, with no preapproval policy. We developed a logistic regression model to assess risk factors associated with 14-day crude mortality. Propensity score for polymyxin was used to control biases. Results Seventy (34%) of 203 patients had infections with at least 1 multidrug-resistant organism isolated from any clinical culture. Polymyxins in monotherapy or in combination therapy were prescribed to 140 of the 203 (69%) patients. The overall 14-day mortality rate was 30%. The 14-day crude mortality was associated with age (adjusted odds ratio [aOR], 1.03; 95% confidence interval [CI], 1.01-1.05; P = .01), SOFA (sepsis-related organ failure assessment) score value (aOR, 1.2; 95% CI, 1.09-1.32; P < .001), CR-GNB infection (aOR, 3.94; 95% CI, 1.53-10.14; P = .005), and time between suspected sepsis and antibiotic administration (aOR, 0.73; 95% CI, .65-.83; P < .001). The empirical use of polymyxins was not associated with decreased crude mortality (aOR, 0.71; 95% CI, .29-1.71; P = .44). Conclusions Empirical use of polymyxin for septic patients in a setting with high CR-GNB prevalence was not associated with decreased crude mortality. In this retrospective cohort study, we found that the empirical use of polymyxin in septic patients was not associated with a decrease in crude mortality, even in a setting with a high prevalence of carbapenem-resistant gram-negative bacteria.
- Trends in Inpatient Antibiotic Use Among Adults Hospitalized During the Coronavirus Disease 2019 Pandemic in Argentina, Brazil, and Chile, 2018-2021(2023) PATEL, Twisha S.; MCGOVERN, Olivia L.; MAHON, Garrett; OSUKA, Hanako; BOSZCZOWSKI, Icaro; MUNITA, Jose M.; GARZON, Maria Isabel; SALOMAO, Matias C.; MARSSOLA, Giovanna; TAVARES, Bruno M.; FRANCISCO, Debora B.; GURGEL, Alessandra P. A.; ARANTES, Tiago; BORI, Andrea; NOGUEIRA, Cassimiro; PETERS, Anne; SPENCER, Maria; ORELLANA, Cristian; BARBE, Mario; LOPEZ, Constanza; STENDER, Stacie; LESSA, Fernanda C.In this ecologic evaluation of antibiotic use among inpatients in Argentina, Brazil, and Chile, substantial increases in antibiotic use were observed during the coronavirus disease 2019 pandemic (March 2020-February 2021) compared with a prepandemic period (March 2018-February 2020). Background High rates of antibiotic use (AU) among inpatients with coronavirus disease 2019 (COVID-19) despite low rates of bacterial coinfection and secondary infection have been reported. We evaluated the impact of the COVID-19 pandemic on AU in healthcare facilities (HCFs) in South America. Methods We conducted an ecologic evaluation of AU in inpatient adult acute care wards in 2 HCFs each in Argentina, Brazil, and Chile. The AU rates for intravenous antibiotics were calculated as the defined daily dose per 1000 patient-days, using pharmacy dispensing records and hospitalization data from March 2018-February 2020 (prepandemic) and March 2020-February 2021 (pandemic). Differences in median AU were compared between the prepandemic and pandemic periods, using the Wilcoxon rank sum test to determine significance. Interrupted time series analysis was used to analyze changes in AU during the COVID-19 pandemic. Results Compared with the prepandemic period, the median difference in AU rates for all antibiotics combined increased in 4 of 6 HCFs (percentage change, 6.7%-35.1%; P < .05). In the interrupted time series models, 5 of 6 HCFs had significant increases in use of all antibiotics combined immediately at the onset of the pandemic (immediate effect estimate range, 15.4-268), but only 1 of these 5 HCFs experienced a sustained increase over time (change in slope, +8.13; P < .01). The effect of the pandemic onset varied by antibiotic group and HCF. Conclusions Substantial increases in AU were observed at the beginning of the COVID-19 pandemic, suggesting the need to maintain or strengthen antibiotic stewardship activities as part of pandemic or emergency HCF responses.
- Procalcitonin as a biomarker for ventilator associated pneumonia in COVID-19 patients: Is it an useful stewardship tool? (vol 101, 115344, 2021)(2022) CORTES, Marina Farrel; ALMEIDA, Bianca Leal de; ESPINOZA, Evelyn Patricia Sanchez; CAMPOS, Aleia Faustina; MOURA, Maria Luiza do Nascimento; SALOMAO, Matias C.; BOSZCZOWSKI, Icaro; FREIRE, Maristela Pinheiro; CARVALHO, Laina Bubach de; PARANHOS-BACCALA, Glaucia; COSTA, Silvia Figueiredo; GUIMARAES, Thais
- Multidrug-resistant Klebsiella pneumoniae: genetic diversity, mechanisms of resistance to polymyxins and clinical outcomes in a tertiary teaching hospital in Brazil(2019) BOSZCZOWSKI, Icaro; SALOMAO, Matias Chiarastelli; MOURA, Maria Luisa; FREIRE, Maristela Pinheiro; GUIMARAES, Thais; CURY, Ana Paula; ROSSI, Flavia; RIZEK, Camila Fonseca; MARTINS, Roberta Cristina Ruedas; COSTA, Silvia FigueiredoIncreased resistance to polymyxin in Klebsiella pneumoniae (ColRKP) has been observed. Molecular epidemiology, as well as the clinical impact of these difficult to treat pathogens need to be better characterized. We present the clinical outcomes of 28 patients infected by ColRKP in a tertiary hospital. Isolates with MIC >2 by Vitek 2 were confirmed by the microdilution broth test. Polymerase chain reaction (PCR) was performed for bla(KPC), bla(NDM), bla(OXA-48), and bla(mcr-1) genes in the isolates, and Whole Genome Sequencing (WGS) was performed in six isolates. Seventeen (61%) patients were female and the mean age was 50 years old. In-hospital and 30-day mortality were 64% (18/28) and 53% (15/28), respectively. Central line-associated bloodstream infection in addition to bacteremia episodes due to other sources were the most frequent (61%). Mean APACHE and Charlson comorbidity index were 16 and 5, respectively. Twenty patients (71%) received at least one active drug and ten (35%) received two drugs: tigecycline 46% (13/28); amikacin 21% (6/28) and fosfomycin 3% (1 case). Twenty-six out of 28 tested cases were positive for bla(KPC) Eight different clusters were identified. Four STs were detected (ST1, ST23, ST340, and ST437). Mutations on pmrA, arnB udg, and yciM genes were present in all six isolates submitted to WGS; /pxMand mgrB mutations were also detected in all but one isolate. In conclusion, we observed resistance to polymyxin in severely ill patients mostly from intensive care units and/or immunosuppressed patients with high mortality rates in whom a diversity of ColRKP clusters was identified and might indicate selective pressure.
- Diagnostic performance of the Xpert Carba-R (TM) assay directly from rectal swabs for active surveillance of carbapenemase-producing organisms in the largest Brazilian University Hospital(2020) CURY, Ana Paula; ALMEIDA JUNIOR, J. N.; COSTA, Silvia F.; SALOMAO, Matias C.; BOSZCZOWSKI, Icaro; DUARTE, Alberto J. S.; ROSSI, FlaviaBackground: The global spread of carbapenemase-producing organisms (CPO) has been considered by international health authorities as a critical public health concern. Brazil has a high CPO prevalence according to distinct publications but many routine microbiology laboratories have only phenotypic resources to evaluate this epidemiological situation, which is time-consuming and detects only carbapenem-resistant isolates missing CPO susceptible expressing a slightly decreased susceptibility. New molecular platforms can detect CPO faster but a local evaluation is essential. Aim: To evaluate the performance of CPO detection direct from rectal swabs with the Xpert Carba-R (TM) assay (Cepheid, Sunnyvale, CA) in the largest Brazilian University Hospital. Methods: A prospective diagnostic accuracy study of CPO was performed with the collection of rectal swabs from patients admitted into the Intensive Care Unit (ICU) and into the Emergency Department (ED) between April and July 2016. The Xpert Carba-R assay results were compared with carbapenem-resistant Enterobacterales (CRE) surveillance cultures plus in-house PCR carbapenemase detection (reference method). In case of discordant results between methods, additional tests were performed. The limit of detection (LoD) for the CRE culture and the Xpert Carba-R (TM) assay were performed with contrived isolates of known carbapenemases genes. Results: A total of 921 clinical rectal swabs were analyzed being 21% (196/921) from the ICU and 79% (725/921) from the ED. Overall, the Xpert Carba-R (TM) assay detected 9.9% (91/921) of CPOs being 9.5% (87/921) positive only for bla(KPC) and 0.4% (4/921) positive only for bla(NDM). The reference method detected 9.1% (84/921) CPO being 77 (8.4%) bla(KPC), 5 bla(VIM) (0.5%) and 2 bla(NDM) (0.2%). No IMP or OXA-48 like gene was detected. Overall, twelve samples, 1.3% (10 bla(KPC), 2 bla(NDM)) were Xpert Carba-R (TM) positive but negative by the reference method. Five isolates (0.5%) were positive for bla(VIM) only by in-house PCR and confirmed to be bla(VIM-2) by DNA sequencing. The Kappa value, sensitivity, specificity, positive/negative predictive values and accuracy of the Xpert Carba-R (TM) assay were; 0.893 (95% confidence interval [CI], 0.842-0.944), 94% (86.7-98.0), 98.6% (97.5-99.3), 86.8% (78.1-93.0), 99.4% (98.6-99.8) and 98.2% (97.3-99.1), respectively. The LoD for bla(KPC) of the Xpert Carba-R (TM) assay and the CRE cultures were 10(1) CFU/swab. Conclusion: The Xpert Carba-R (TM) assay is an accurate test to detect CPO directly from the rectal swabs with significant lower turnaround time (TAT) when compared to the reference method (CRE culture plus in-house PCR). Xpert Carba-R (TM) may, therefore, be regarded as a good and fast epidemiological tool.
- Transmission of Carbapenem-Resistant Enterobacterales in an Overcrowded Emergency Department: Controlling the Spread to the Hospital(2023) SALOMAO, Matias C.; FREIRE, Maristela P.; LAZARI, Carolina S.; CURY, Ana P.; ROSSI, Flavia; SEGURADO, Aluisio A. C.; COSTA, Silvia F.; LEVIN, Anna S.; BOSZCZOWSKI, IcaroThis quasi-experimental study shows that early contact precautions and rapid identification of patients colonized with carbapenem-resistant Enterobacterales was associated with a nonsignificant reduction of cross-transmission in emergency departments. Background Overcrowded emergency departments (EDs) may increase the risk of carbapenem-resistant Enterobacterales (CRE) transmission. Methods We conducted a quasi-experimental study divided into 2 phases (baseline and intervention) to investigate the impact of an intervention on the acquisition rate and identify risk factors for CRE colonization in an ED of a tertiary academic hospital in Brazil. In both phases, we did universal screening with rapid molecular test (bla(KPC), bla(NDM), bla(OXA48), bla(OXA23), and bla(IMP)) and culture. At baseline, both screening test results were not reported, and patients were put under contact precautions (CP) based on previous colonization or infection by multidrug-resistant organisms. During the intervention, all patients hospitalized in the ED were placed in empiric CP and the result of CRE screening was reported; if negative, patients were released from CP. Patients were rescreened if they stayed >7 days in the ED or were transferred to an intensive care unit. Results A total of 845 patients were included: 342 in baseline and 503 in intervention. Colonization at admission was 3.4% by culture and molecular test. Acquisition rates during ED stay dropped from 4.6% (11/241) to 1% (5/416) during intervention (P = .06). The aggregated antimicrobial use in the ED decreased from phase 1 to phase 2 (804 defined daily doses [DDD]/1000 patients to 394 DDD/1000 patients, respectively). Length of stay >2 days in the ED was a risk factor for CRE acquisition (adjusted odds ratio, 4.58 [95% confidence interval, 1.44-14.58]; P = .01). Conclusions Early empiric CP and rapid identification of CRE-colonized patients reduce cross-transmission in ED. Nevertheless, staying >2 days in ED compromised efforts.
- Increased Risk for Carbapenem-Resistant Enterobacteriaceae Colonization in Intensive Care Units after Hospitalization in Emergency Department(2020) SALOMAO, Matias Chiarastelli; FREIRE, Maristela Pinheiro; BOSZCZOWSKI, Icaro; RAYMUNDO, Sueli F.; GUEDES, Ana Rubia; LEVIN, Anna S.Carbapenem-resistant Enterobacteriaceae (CRE) colonization is common in hospital patients admitted to intensive care units (ICU) from the emergency department. We evaluated the effect of previous hospitalization in the emergency department on CRE colonization at ICU admission. Our case-control study included 103 cases and 201 controls; cases were patients colonized by CRE at admission to ICU and controls were patients admitted to ICU and not colonized. Risk factors were emergency department stay, use of carbapenem. Simplified Acute Physiology Score, upper digestive endoscopy, and transfer from another hospital. We found that ED stay before ICU admission was associated with CRE colonization at admission to the ICU. Our findings indicate that addressing infection control problems in EDs will help to control carbapenem resistance in ICUs.
- Procalcitonin as a biomarker for ventilator associated pneumonia in COVID-19 patients: Is it an useful stewardship tool?(2021) CORTES, Marina Farrel; ALMEIDA, Bianca Leal de; ESPINOZA, Evelyn Patricia Sanchez; CAMPOS, Aleia Faustina; MOURA, Maria Luiza do Nascimento; SALOMAO, Matias C.; BOSZCZOWSKI, Icaro; FREIRE, Maristela Pinheiro; CARVALHO, Laina Bubach de; PARANHOS-BACCALA, Glaucia; COSTA, Silvia Figueiredo; GUIMARAES, ThaisVentilator associated pneumonia(VAP) is a severe complication that can lead to high mortality when not early identified or when therapy is delayed. The aim of this study was to evaluate procalcitonin(PCT) as a biomarker for VAP development. In total, 73 hospitalized patients with COVID-19 were analyzed. PCT levels greater than 0.975ng/mL were more related to VAP. No association was found for C-reactive protein (CRP). The results show that procalcitonin may be a pertinent biomarker for VAP diagnosis and can be a helpful tool for antibiotic withdrawal.